Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gaëtane Simon"'
Autor:
Antoine Vasseur, Matthieu Carton, Severine Guiu, Paule Augereau, Lionel Uwer, Marie-Ange Mouret-Reynier, Christelle Levy, Jean-Christophe Eymard, Jean-Marc Ferrero, Marianne Leheurteur, Anthony Goncalves, Marie Robert, Thibault De La Motte Rouge, Thomas Bachelot, Thierry Petit, Marc Debled, Thomas Grinda, Isabelle Desmoulins, Laurence Vanlemmens, Vincent Nicolaï, Gaëtane Simon, Luc Cabel
Publikováno v:
Breast, Vol 65, Iss , Pp 136-144 (2022)
Background: Taxanes are one of the most effective chemotherapies (CT) in breast cancer (BC), but the efficacy of taxanes rechallenge in early metastatic relapse has been poorly studied in patients previously treated by taxanes in the (neo)adjuvant se
Externí odkaz:
https://doaj.org/article/3e5e3d1b6d254f9091fd5376422aa2e4
Autor:
Marion Bertho, Julien Fraisse, Anne Patsouris, Paul Cottu, Monica Arnedos, David Pérol, Anne Jaffré, Anthony Goncalves, Marie-Paule Lebitasy, Véronique D’Hondt, Florence Dalenc, Jean-Marc Ferrero, Christelle Levy, Sandrine Dabakuyo, Roman Rouzier, Frédérique Penault-Llorca, Lionel Uwer, Jean-Christophe Eymard, Mathias Breton, Michaël Chevrot, Sébastien Thureau, Thierry Petit, Gaëtane Simon, Jean-Sébastien Frénel
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Bone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far. Method
Externí odkaz:
https://doaj.org/article/e5b9bcf3684642038d8891a42d6e9907
Autor:
Tina Lamy, Bastien Cabarrou, David Planchard, Xavier Quantin, Sophie Schneider, Michael Bringuier, Benjamin Besse, Nicolas Girard, Christos Chouaid, Thomas Filleron, Gaëtane Simon, Capucine Baldini
Publikováno v:
Cancers, Vol 14, Iss 1, p 92 (2021)
Background: Genomic and immunologic tumor biomarker testing has dramatically changed the prognosis of patients, particularly those treated for advanced/metastatic non-squamous non-small-cell lung cancer (aNSCLC) when access to targeted agents is avai
Externí odkaz:
https://doaj.org/article/87047e9785614b64afb65b5d8f2ae745